GTS Securities’s Novavax NVAX Stock Holding History

GTS Securities’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-46,501	Closed	-$587K	–	3146
2024 Q3	$587K	Buy	+46,501	New	+$600K	﹤0.01%	2664
2023 Q4	–	Sell	-11,863	Closed	-$72.6K	–	4293
2023 Q3	$85.9K	Buy	+11,863	New	+$94.8K	﹤0.01%	3626

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

GTS Securities's NVAX Position: Q4 2024 in Review

GTS Securities sold out of Novavax (NVAX) in Q4 2024, closing a stake of 46,501 shares — an estimated $587K sold.

GTS Securities first reported a position in NVAX in Q3 2023 and held it in 2 quarters. The position peaked at $587K in Q3 2024. 234 funds tracked by Wall St. Rank hold NVAX as of Q4 2024.

GTS Securities reported no remaining Novavax position as of Q4 2024 after selling out during the quarter.
GTS Securities sold 46,501 Novavax shares in Q4 2024, an estimated $587K.
GTS Securities first reported a position in Novavax in Q3 2023 and held it in 2 quarters.
GTS Securities's Novavax position peaked at $587K in Q3 2024.
234 funds tracked by Wall St. Rank held Novavax as of Q4 2024.

Based on GTS Securities's 13F filing for Q4 2024, filed 18 Feb 2025.